Background
Brian Rifkin
Mind The Gap: When eGFR Creatinine and Cystatin ...

This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

Mind The Gap: When eGFR Creatinine and Cystatin C Disagree
Background
Cristina Adriana Popa
A dose of CONFIDENCE: Building evidence for ...

This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.

A dose of CONFIDENCE: Building evidence for finerenone-empagliflozin synergy in diabetic kidney disease
Background
swapnil hiremath
From single shots to strategy: How CAPTIVATE is ...

Summary of the CAPTIVATE platform which will be a twitter spaces discussion

From single shots to strategy: How CAPTIVATE is reframing the NephTrials playbook
Background
Cristina Adriana Popa
Are E-Nudges Enough to Push Guideline-Based CKD ...

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

Are E-Nudges Enough to Push Guideline-Based CKD Therapy?
Background
Brian Rifkin
STAMP of Approval: Tacrolimus vs MMF in ...

This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?

STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome

lancet

Patiromer, spironolactone and resistant hypertension.

Patiromer, spironolactone and resistant hypertension.

The new generation of potassium binders bind potassium but can they improve patient outcomes? These second order questions are starting to be answered. Join us this week to discuss the use of patiromer and spironolactone in patients with resistant hypertension.The AMBER Study